drugset / Trial / NCT02187198
Buprenorphine Treatment for Opioid Dependence
RandomizedParallel-groupOpen-labelTreatment
Summary
Buprenorphine/naloxone (BUP/NLX) treatment is effective for the treatment of prescription opioid dependence, previous studies have not determined the optimum dose of BUP/NLX for this patient population. The goal of this study is to determine if there are differences in clinical efficacy of BUP/NLX tablet in low dose range (less than or equal to 8/2mg) vs. high dose range (greater than or equal to 16, range 16-24mg). The main outcomes of interest will be treatment retention, use of opioids, and the use of other drugs of abuse.
Timeline
- Start
- 2015-03
- Primary completion
- 2022-02-01
- Completion
- 2023-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buprenorphine | Other / unclassified | 8 mg | — |
| Subject | Buprenorphine | Other / unclassified | 16 mg | — |
| Subject | Buprenorphine | Other / unclassified | 24 mg | — |